X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Under the agreement, BioSyent extended its agreement with its European partner for the RepaGyn (sodium hyaluronate) and Proktis-M products, extending its exclusive Canadian rights to these products until 2032.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Repagyn
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2024
Details:
The agreement aims to develop respirable, dry powder formulations of high molecular weight hyaluronan for treating or preventing respiratory diseases with a primary focus on COPD and viral respiratory diseases caused by SARS-CoV-2, influenza virus, and RSV.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Environmental Health Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2023
Details:
Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.
Lead Product(s): Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area: Musculoskeletal Product Name: Cingal
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: I-Defense
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: I-MED
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 15, 2021
Details:
Researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented hyaluronan improves lung function in patients suffering from severe exacerbation of chronic obstructive pulmonary disease (COPD).
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: HMW-HA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
LOA2 met its primary endpoint of non-inferiority vs. comparator at the 3-month time point in corneal staining with a p value of 0.001. LO2A continued, as in prior trials, to demonstrate a good safety profile with no major adverse events or side effects reported.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: LO2A
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bonus BioGroup
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Agreement January 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
